Schedule I in US; FDA rejected Lykos NDA August 2024; Transcend/Otsuka methylone analog in Phase 3
Reporting + research wiki
Psychedelics as a reported story and a living record.
Spare Change of Mind tracks psychedelic medicine across trials, companies, regulators, history, and consciousness, with an editorial front end backed by a growing research wiki built for citations, entity linking, and context that compounds.
There is something a little odd about asking an AI to help keep careful notes on one of the strangest stories in medicine. That is part of the experiment here. The bar is still the same: make it readable, make it sourced, and make it useful.
Join the early SCM list.
Add your email if you want future Spare Change of Mind reporting updates. This pass only captures signups into the editorial system, it does not send outbound email yet.
Thanks, you’re on the list.
Please enter a valid email address.
Something went wrong while saving your signup. Please try again.
Follow the reporting as it lands.
Start with the archive to track the latest stories across trials, companies, regulators, and psychedelic history.
Primary research surface
Start with the recurring entities and institutions behind the coverage.
Schedule I in US; approved in Australia for TRD and PTSD; extensive Phase 2/3 trials globally
Seeking Phase 3 redesign following FDA Complete Response Letter (August 2024)
Active regulator for multiple psychedelic INDs; midomafetamine NDA reviewed in June 2024 and later rejected via Complete Response Letter
Active nonprofit research and policy organization; MDMA-assisted therapy remains investigational and MAPS continues public education and program context
Use the wiki as a map of companies, compounds, concepts, and regulators.
Follow the dossiers that moved most recently.
Phase 3 COMP360 for TRD underway; FDA accepted IND application for PTSD in January 2026
Phase 3 PARADIGM program underway for HLP003/CYB003 in major depressive disorder
Seeking Phase 3 redesign following FDA Complete Response Letter (August 2024)
Active nonprofit research and policy organization; MDMA-assisted therapy remains investigational and MAPS continues public education and program context
Latest reporting
GH001 After the Clinical Hold Lift: What Actually Changed
GH001's FDA clinical hold is over, and the program now has a peer-reviewed phase 2b paper in JAMA Psychiatry. That is real progress, but it is not the same thing as pivotal proof or an FDA endorsement of efficacy.
How a Mazatec healer in Huautla de Jiménez and a New York banker became central, unequal figures in the story of how psilocybin entered Western public awareness.
How Richard Alpert became Ram Dass, why Be Here Now mattered, and how his path diverged from Timothy Leary's while still sharing psychedelic roots.
How Albert Hofmann's Sandoz compound moved from laboratory chemistry into psychiatry, Cold War intelligence programs, and the American counterculture.
The paper behind the headline did find DMT and harmine in a 1,000-year-old ritual bundle from southwestern Bolivia. It did not prove a prepared ayahuasca brew. What it does show is broader and more defensible: multiple psychoactive plants, long-distance movement, and sophisticated botanical knowledge in the pre-Columbian Andes.
The best-supported answer still begins at 5-HT2A, but the downstream story on plasticity and biomarkers is much less settled.
First full week roundup.